Zolpidem (Stilnow) is Most Likely to Cause Delirium
Among the three medications, zolpidem (Stilnow) carries the highest risk for delirium and delirium-related cognitive impairment, followed by melatonin, while lemborexant (Dayvigo) appears to have the lowest risk and may actually prevent delirium.
Evidence-Based Risk Hierarchy
Zolpidem (Stilnow) - Highest Risk
Zolpidem is associated with serious neuropsychiatric adverse effects that directly relate to delirium risk:
Cognitive impairment profile: FDA data and guidelines document that zolpidem causes amnesia, vertigo, confusion, and diplopia 1. In older patients specifically, sedative-hypnotics including zolpidem resulted in a 5-fold increase in memory loss, confusion, and disorientation 1.
Psychiatric adverse events: Medical reviews for the FDA indicated zolpidem resulted in higher incidence of psychiatric adverse events and memory impairment 1.
Recent comparative evidence: A 2026 review confirmed zolpidem was commonly linked to complex sleep behaviors, amnesia, and hallucinations, particularly at higher doses and in patients with psychiatric comorbidities 2.
Benzodiazepine-class effects: One study found benzodiazepines significantly increased delirium risk (aOR 1.90), and zolpidem shares similar GABA-ergic mechanisms 3.
Melatonin - Intermediate Risk
The evidence for melatonin is paradoxical and context-dependent:
Protective in some settings: Meta-analysis showed melatonin/ramelteon reduced delirium incidence by 39% overall (RR 0.61), with benefits primarily in surgical (49% reduction) and ICU patients (34% reduction) 4.
No benefit in medical patients: The same analysis found non-significant reduction in general medical patients 4.
Recent contradictory findings: However, multiple 2026 meta-analyses found melatonin showed no significant effect on delirium prevention in RCTs (RR 0.94; 95% CI 0.72-1.22) 5. Another found melatonin was associated with higher observed dementia risk compared to both benzodiazepines and zolpidem, though this likely reflects confounding by indication rather than causation 6.
Adverse effects: Hallucinations, nightmares, and gastrointestinal disorders were prevalent in the melatonin group 4.
Lemborexant (Dayvigo) - Lowest Risk
Lemborexant appears protective against delirium rather than causative:
Delirium prevention: A 2024 retrospective cohort study found lemborexant significantly reduced delirium risk (aOR 0.23; 95% CI 0.14-0.39; P < 0.0001) 3. This represents a 77% risk reduction.
Orexin antagonist class effect: Meta-analyses of dual orexin receptor antagonists (DORAs) including lemborexant showed 40-46% relative risk reductions in delirium prevalence 7. In RCTs, orexin receptor antagonists were associated with lower delirium risk (RR 0.55; 95% CI 0.35-0.87) 5.
FDA safety profile: The FDA label for Dayvigo warns of cognitive and behavioral changes, hallucinations, and complex sleep behaviors, but clinical trial data showed hypnagogic hallucinations in only 0.7% (10 mg dose) and sleep paralysis in 1.6% 8. These rates are substantially lower than zolpidem's cognitive impairment rates.
Lower neuropsychiatric burden: Compared to zolpidem's 5-fold increase in confusion and disorientation, lemborexant's primary adverse effect was somnolence (10% vs 1% placebo), not delirium-spectrum symptoms 8.
Clinical Algorithm for Selection
When delirium risk is a primary concern:
- First-line: Lemborexant (Dayvigo) 5 mg - actively reduces delirium risk
- Avoid: Zolpidem (Stilnow) - highest risk for confusion, amnesia, and delirium
- Context-dependent: Melatonin - may help in surgical/ICU settings but ineffective in general medical patients
Critical Caveats
For lemborexant users who still develop delirium (28.6% in one cohort 9), risk factors include:
- Advanced age (aOR 1.05 per year)
- Concomitant benzodiazepines (aOR 2.19)
- Co-administration with ramelteon (aOR 2.85)
- Other potentially deliriogenic medications (aOR 1.94)
Therefore, use lemborexant as monotherapy without benzodiazepines or ramelteon to maximize delirium prevention.
The evidence strongly supports avoiding zolpidem in patients at risk for delirium, considering melatonin only in specific surgical/ICU contexts, and preferentially using lemborexant which demonstrates both efficacy for insomnia and delirium prevention 3, 7.